We confirmed the results of our screen and showed that sorafenib markedly inhibited the gefitinib-induced increase in the proportion of EGFR-T790M mutant cells in different EGFR-addicted NSCLC lines (Fig. 1C). Here, EGFR is linked to non-small cell lung carcinoma.